Literature DB >> 29795428

Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.

Motohiro Kato1,2, Mio Kurata3, Junya Kanda4, Koji Kato5, Daisuke Tomizawa6, Kazuko Kudo7, Nao Yoshida5, Kenichiro Watanabe8, Hiroyuki Shimada9, Jiro Inagaki10, Katsuyoshi Koh11, Hiroaki Goto12, Keisuke Kato13, Yuko Cho14, Yuki Yuza15, Atsushi Ogawa16, Keiko Okada17, Masami Inoue18, Yoshiko Hashii19, Takanori Teshima20, Makoto Murata21, Yoshiko Atsuta3,22.   

Abstract

Graft-versus-host disease (GVHD) occasionally leads to morbidity and mortality but is thought to reduce the risk of relapses in patients with a hematological malignancy. However, information on the effect of GVHD in pediatric leukemia is limited. Using a nationwide registry, we retrospectively analyzed 1526 children who underwent allogeneic stem cell transplantation for leukemia. Grades 0-I acute GVHD were associated with a higher relapse rate at three years after transplantation, at 25.4 and 24.3%, respectively, than grades II, III, or IV acute GVHD at 18.9%, 21.2%, and 2.6%, respectively. In contrast, the overall survival curve of the grades 0 and I GVHD groups (79.0% and 79.5%, respectively) approximated that of the grade II GVHD group (76.3%), and the probability of survival was worst in the severe GVHD groups (66.9% for grade III and 42.5% for grade IV). Chronic GVHD also reduced the relapse risk but conferred no survival advantage. Acute lymphoblastic leukemia was more sensitive to acute GVHD than acute myeloid leukemia (AML) while AML was more sensitive to chronic GVHD. Our study reproduced the preventive effects of GVHD against pediatric leukemia relapses but failed to demonstrate a significant survival advantage.

Entities:  

Year:  2018        PMID: 29795428     DOI: 10.1038/s41409-018-0221-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse.

Authors:  Supinya Iamsawat; Linlu Tian; Anusara Daenthanasanmak; Yongxia Wu; Hung D Nguyen; David Bastian; Xue-Zhong Yu
Journal:  Blood Adv       Date:  2019-12-23

Review 2.  Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.

Authors:  Katsutsugu Umeda
Journal:  Int J Hematol       Date:  2022-05-14       Impact factor: 2.490

3.  Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature.

Authors:  Antonio G Grasso; Marilena Granzotto; Davide Zanon; Alessandra Maestro; Stefano Loiacono; Natalia Maximova
Journal:  Cancers (Basel)       Date:  2018-08-27       Impact factor: 6.639

Review 4.  The Graft-Versus-Leukemia Effect in AML.

Authors:  Connor Sweeney; Paresh Vyas
Journal:  Front Oncol       Date:  2019-11-19       Impact factor: 6.244

5.  Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation.

Authors:  C R S Uppugunduri; P Huezo-Diaz Curtis; T Nava; M A Rezgui; V Mlakar; S Jurkovic Mlakar; N Waespe; Y Théoret; F Gumy-Pause; F Bernard; Y Chalandon; J J Boelens; R G M Bredius; J H Dalle; C Nath; S Corbacioglu; C Peters; P Bader; P Shaw; H Bittencourt; M Krajinovic; M Ansari
Journal:  Pharmacogenomics J       Date:  2021-10-28       Impact factor: 3.550

6.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

7.  Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Prioty Islam; Helen Tang; Haesu Jin; Felicia Cao; Lauren M Bohannon; Yi Ren; Nelson J Chao; Taewoong Choi; Cristina Gasparetto; Mitchell E Horwitz; Gwynn D Long; Richard D Lopez; David A Rizzieri; Stefanie Sarantopoulos; Anthony D Sung
Journal:  Transplant Cell Ther       Date:  2021-06-17

8.  Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors.

Authors:  Masaharu Tamaki; Kazuaki Kameda; Shun-Ichi Kimura; Naonori Harada; Naoyuki Uchida; Noriko Doki; Masatsugu Tanaka; Kazuhiro Ikegame; Masashi Sawa; Yuta Katayama; Shigesaburo Miyakoshi; Takahide Ara; Junya Kanda; Makoto Onizuka; Takahiro Fukuda; Yoshiko Atsuta; Yoshinobu Kanda; Kimikazu Yakushijin; Hideki Nakasone
Journal:  Blood Adv       Date:  2022-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.